ClinicaliQ Trial Snapshot
- A Study of Navenibart in Participants With Hereditary Angioedema — Recruiting • Phase III • Cardiology / Cardiovascular • NCT06842823.
- What is being tested: Navenibart, a subcutaneous treatment for hereditary angioedema (HAE types 1 and 2), is being evaluated in a Phase 3 randomised controlled trial to assess its safety and efficacy in preventing angioedema attacks.
- Patient eligibility: The trial includes adult and adolescent participants diagnosed with type 1 or type 2 HAE, representing the two most common genetic forms of this rare condition affecting complement-mediated inflammation.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Eligibility Snapshot
- : * Documented diagnosis of HAE (Type 1 or 2). The following must be met: 1. Documented clinical history consistent with HAE 2. Lab findings consistent with HAE Type 1 or 2 * Experienced at least 2 HAE attacks during the Run-In period, as confirmed by an investigator based on meeting the protocol-specified definition of an HAE attack.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.